Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11890404 | 0.86 | HTR2A (0.39) | KCNH2HTR2ASLC6A4MEN1MAPT | |
| SCHEMBL16959139 | 0.85 | KCNH2 (0.38) | KCNH2HTR2ASLC6A4TMEM97SIGMAR1 | |
| SCHEMBL9945955 | 0.84 | RXRA (0.41) | KCNH2HTR2ASLC6A4TMEM97SIGMAR1 | |
| SCHEMBL8119851 | 0.82 | NFE2L2 (0.43) | KCNH2HTR2ASLC6A4ALDH1A1 | |
| SCHEMBL16954897 | 0.80 | KCNH2 (0.35) | KCNH2HTR2ASLC6A4TMEM97SIGMAR1 | |
| SCHEMBL5745812 | 0.79 | MEN1 (0.50) | KCNH2SLC6A4TMEM97SIGMAR1ACLY | |
| SCHEMBL11890399 | 0.78 | L3MBTL1 (0.43) | KCNH2HTR2ASLC6A4MAPTL3MBTL1 | |
| SCHEMBL16954024 | 0.78 | KCNH2 (0.36) | KCNH2HTR2ASLC6A4TMEM97SIGMAR1 | |
| SCHEMBL8988166 | 0.78 | LMNA (0.38) | CSNK2A1MAPTHPGDALDH1A1 | |
| SCHEMBL12569380 | 0.78 | SLC6A4 (0.41) | KCNH2HTR2ASLC6A4TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8445480-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | KCNH2 3067/4885HTR2A 7/4885SLC6A4 83/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | KCNH2 2439/4885HTR2A 4562/4885SLC6A4 4692/4885 |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | KCNH2 3407/4885HTR2A 3209/4885SLC6A4 3857/4885 |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | KCNH2 2428/4885HTR2A 2572/4885SLC6A4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.